Skip to content
Review

Abstract PR002: Surveillance-detected pancreatic cancers: Updated report from the PRECEDE Consortium

Sep 2026 · Cancer Research · Vol 86, pp. PR002-PR002 · 0 citations

TL;DR

The Pancreatic Cancer Early Detection (PRECEDE) Consortium is a multinational prospective longitudinal cohort study of participants with elevated heritable risk for pancreatic adenocarcinoma, with an overarching goal to increase survival of PC by driving early detection.

Abstract

The Pancreatic Cancer Early Detection (PRECEDE) Consortium is a multinational prospective longitudinal cohort study of participants with elevated heritable risk for pancreatic adenocarcinoma (PC). PRECEDE aims to support surveillance for high-risk individuals (HRIs) to inform clinical practice and public health policy, with an overarching goal to increase survival of PC by driving early detection. Here we characterize PCs detected in PRECEDE participants to date, with the goal to quantify clinical implications of PC diagnoses within real-world surveillance and early detection programs across the globe. PRECEDE participants (n=12,213) are enrolled at 65 active sites, including 7,337 HRIs meeting NCCN or ASGE criteria for PC surveillance. Those enrolled to surveillance between 5/1/2020 and 7/1/2026 and subsequently diagnosed with PC are included. Standard PRECEDE data include clinical and demographic data, family history, pathogenic germline variants (PGVs), surveillance and diagnostic imaging data, and tumor characteristics from surgical and pathology reports. PC cases beyond Stage 1 are reviewed at an ongoing multi-disciplinary PRECEDE monthly clinical conference. 52 participants have been diagnosed with PC to date, including 47 with prior imaging (incident PC) and 4 at enrollment (prevalent PC); the most recent case, data pending, is omitted. Of 51 cases, median age at diagnosis was 68 years (range 38-84), 47 (92%) met NCCN or ASGE surveillance guidelines, and 72.5% (37/51) had at least one PGV in a gene linked to PC risk (14 BRCA2, 8 CDKN2A, 7 ATM, 7 BRCA1, 2 CHEK2, 1 APC, 1 MSH2), 3 were in follow up for a pancreatic cystic neoplasm < 1 cm with a single first degree relative with PC, and one for dilated main pancreatic duct with a known PGV in MSH2. Of 21 BRCA1/2 carriers, 9 had no family history of PC. All 4 prevalent PCs had stage III/IV disease. Among 47 incident cases, median years from first surveillance to diagnosis was 3.50 (SD 6.12; range: 0.05 – 30.21), and 31 (66.0%) had stage 0/I disease, with 9 (19.1%) stage II, and 7 (14.9%) stage III/IV. Among 68,538 PC cases in the SEER database, only 11.2% were stage 0/I, a difference of 54.8 percentage points (95% Agresti-Caffo confidence interval for the difference 66.0% vs 11.2%: 40.8%, 67.4%; p < 0.001). The proportion of stage 0/1 tumors in incident PRECEDE cases was significantly higher than in SEER population data (66.0% vs 11.2%); however, 14.9% were stage III/IV at diagnosis despite prior normal imaging. Multidisciplinary central review of cases beyond stage 0/1 is underway to investigate potential causes, including missed/delayed surveillance, or missed findings on prior imaging. Whole genome tumor sequencing will also be performed to investigate cases of rapid progression to metastatic disease. Ongoing study of incident PC cases from this longitudinal surveillance population will enable more accurate risk stratification and effective surveillance protocols with the potential for improved rates of early detection. Raymond Wadlow, Samuel Newton, Jessica Everett, Nandita Rangu, Karen Messer, Jiayu Chen, Randall Brand, Teresa Brentnall, Daniel Chung, Julie Earl, Whitney Espinel, James Farrell, Kurt Giles, Talia Golan, Ora Gordon, John Graff, Aaron Grossberg, Bryson Katona, Richard Kwon, Andrew Lowy, Aimee Lucas, Meg Mandelson, Salvatore Paiella, Elena Stoffel, Margaret Tempero, David Weinberg, Dana Zakalik, George Zogopoulos, Diane M. Simeone. Surveillance-detected pancreatic cancers: Updated report from the PRECEDE Consortium [abstract]. In: Proceedings of the AACR Conference on Pancreatic Cancer: New Frontiers in Biology and Therapeutic Development; 2026 Sep 25-28; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2026;86(18_Suppl_2):Abstract nr PR002.

View source

Similar papers

Sep 2026

Predicting pancreatic cancer in high-risk individuals and in the general population: how long is the road yet?

It is emphasized that the future effectiveness of PDAC prevention lies in refined risk stratification through universal germline testing, the integration of polygenic and environmental data, and the provision of comprehensive psychosocial support to manage the emotional impact of surveillance.

D. Campa, C. Rizzato, A. Kataki et al. · 0 citations
Sep 2026

Abstract A089: Implementation of an early detection program for pancreatic cancer using electronic health record-based risk prediction models

Early detection remains a major challenge in pancreatic cancer (PC). We evaluated the feasibility of implementing an electronic health record (EHR)-based screening program that uses a validated risk prediction algorithm to identify patients at elevated risk for PC and offer targeted cross-sectional imaging....

T. Luong, Jessica Moore, Qiao-Ling Chen et al. · 0 citations
Review Oct 2026

Prevention Before Therapy in Pancreatic Ductal Adenocarcinoma: The Clinical, Economic, and Human Case for Weighting Resources Upstream.

Pancreatic ductal adenocarcinoma (PDAC) is projected to become the second-leading cause of US cancer death by 2030, and survival is dominated by stage at diagnosis: roughly 44% at five years for localized disease versus about 3% with distant metastases. Only about 15% of cases are detected while localized, surgery reac...

G. Eibl, O. J. Hines, Enrique Rozengurt · 0 citations
Review Open access Oct 2026

Early-Onset Colorectal Cancer: Molecular Features, Risk Stratification, Screening Gaps, and Personalized Prevention

Although overall colorectal cancer (CRC) incidence and mortality have declined with widespread screening, early-onset CRC (EOCRC), defined as diagnosis before age 50, continues to rise. EOCRC partially differs from late-onset CRC (LOCRC) in clinical presentation, molecular features, polyp characteristics, and patterns...

Vanessa Lu, Fiona Xu, G. Graziosi et al. · 0 citations
Review Open access Oct 2026

Receipt of surveillance in a population-based sample of survivors of early-onset colorectal cancer.

638 Background: Early-onset colorectal cancer (EOCRC) incidence is rising but data on survival and recurrence compared with late-onset CRC remain limited, contributing to under- and over-use of surveillance. We evaluated receipt of surveillance in a diverse population-based sample of EOCRC survivors and identif...

Christine M. Veenstra, E. Stoffel, S. Hawley et al. · 0 citations
Review Open access Oct 2026

Liquid biopsy in pancreatic ductal adenocarcinoma from diagnostic accuracy to clinical utility

Pancreatic ductal adenocarcinoma (PDAC) is often diagnosed after the opportunity for curative treatment has passed. Blood-based biomarkers offer opportunities for earlier detection and serial molecular assessment, but their value depends on the intended clinical use. This nonsystematic narrative review critically exami...

Konstantinos Kossenas, N. Garmpis, Nikolaos Karountzos et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.